Increase of circulating CD4+CD25highFoxp3+ Regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2

Journal of Immunotherapy

Volumn 33, Issue 4, 2010, Pages 425-434

  Berntsen, Annika ^a   Brimnes, Marie Klinge ^a   Straten, Per Thor ^a   Svane, Inge Marie ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Dendritic cell vaccination; IL 2; IL 21; Metastatic renal cell carcinoma; Mrcc; Regulatory T cells

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 21; RECOMBINANT INTERLEUKIN 2; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CELL COUNT; CELL ISOLATION; CELL PROLIFERATION; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG ACTIVITY; FLOW CYTOMETRY; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTE COUNT; METASTASIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; VACCINATION;

ADULT; AGED; ANTIGENS, CD4; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL PROLIFERATION; CELLS, CULTURED; COCULTURE TECHNIQUES; DENDRITIC CELLS; DISEASE PROGRESSION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTERLEUKINS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; T-LYMPHOCYTES, REGULATORY;

EID: 77954953523     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181cd870f     Document Type: Article

References (50)

1. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295-307.
2. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108:804-811.
3. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8:523-532.
4. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother. 2007;56:1743-1753.
5. Jensen HK, Donskov F, Nordsmark M, et al. Increased intratumoral FOXP3-positive regulatory immune cells during interleukin-2 treatment in metastatic renal cell carcinoma. Clin Cancer Res. 2009;15:1052-1058.
6. Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res. 2005;11:8326-8331.
7. Hiraoka N, Onozato K, Kosuge T, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423-5434.
8. Gao Q, Qiu SJ, Fan J, et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007;25:2586-2593.
9. Needham DJ, Lee JX, Beilharz MW. Intra-tumoural regulatory T cells: a potential new target in cancer immunotherapy. Biochem Biophys Res Commun. 2006;343:684-691.
10. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999;163:5211-5218.
11. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccinemediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623-3633.
12. Baecher-Allan C, Brown JA, Freeman GJ, et al. CD4+CD25 high regulatory cells in human peripheral blood. J Immunol. 2001;167:1245-1253.
13. Dieckmann D, Plottner H, Berchtold S, et al. Ex vivo isolation and characterization of CD4 (+) CD25 (+) T cells with regulatory properties from human blood. J Exp Med. 2001;193:1303-1310.
14. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057-1061.
15. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003;4:330-336.
16. Allan SE, Crome SQ, Crellin NK, et al. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol. 2007;19:345-354.
17. Morgan ME, Van Bilsen JH, Bakker AM, et al. Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. Hum Immunol. 2005;66:13-20.
18. Tran DQ, Ramsey H, Shevach EM. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype. Blood. 2007;110:2983-2990.
19. Liu W, Putnam AL, Xu-Yu Z, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203:1701-1711.
20. Kleinewietfeld M, Starke M, Di Mitri D, et al. CD49d provides access to "untouched" human Foxp3+ Treg free of contaminating effector cells. Blood. 2009;113:827-836.
21. Marie JC, Letterio JJ, Gavin M, et al. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005;201:1061-1067.
22. Huber S, Schramm C, Lehr HA, et al. Cutting edge: TGF-beta signaling is required for the in vivo expansion and immunosuppressive capacity of regulatory CD4+CD25+ T cells. J Immunol. 2004;173:6526-6531.
23. Atkins MB. Interleukin-2: clinical applications. Semin Oncol. 2002;29:12-17.
24. Bayer AL, Yu A, Adeegbe D, et al. Essential role for interleukin-2 for CD4 (+) CD25 (+) T regulatory cell development during the neonatal period. J Exp Med. 2005;201:769-777.
25. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25 (hi) Foxp3+ regulatory T cells in cancer patients. Blood. 2006;107:2409-2414.
26. Fontenot JD, Rasmussen JP, Gavin MA, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005;6:1142-1151.
27. Cesana GC, DeRaffele G, Cohen S, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006;24:1169-1177.
28. Van der Vliet HJ, Koon HB, Yue SC, et al. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer. Clin Cancer Res. 2007;13:2100-2108.
29. Davis ID, Skak K, Smyth MJ, et al. Interleukin-21 signaling: functions in cancer and autoimmunity. Clin Cancer Res. 2007;13:6926-6932.
30. Berntsen A, Trepiakas R, Wenandy L, et al. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother. 2008;31:771-780.
31. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+ regulatory T cells. Semin Immunol. 2004;16:89-98.
32. Chen W, Jin W, Hardegen N, et al. Conversion of peripheral CD4+. J Exp Med. 2003;198:1875-1886.
33. Berntsen A, Geertsen PF, Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol. 2006;50:34-43.
34. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263-274.
35. Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004;4:665-674.
36. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol. 1999;163:1690-1695.
37. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J Clin Oncol. 2004;22:4474-4485.
38. Zhang H, Chua KS, Guimond M, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med. 2005;11:1238-1243.
39. Zorn E, Nelson EA, Mohseni M, et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006;108:1571-1579.
40. Vukmanovic-Stejic M, Zhang Y, Cook JE, et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest. 2006;116:2423-2433.
41. Cools N, Ponsaerts P, Van Tendeloo VF, et al. Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. J Leukoc Biol. 2007;82:1365-1374.
42. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4 (+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000;192:1213-1222.
43. Verhasselt V, Vosters O, Beuneu C, et al. Induction of FOXP3-expressing regulatory CD4pos T cells by human mature autologous dendritic cells. Eur J Immunol. 2004;34:762-772.
44. Banerjee DK, Dhodapkar MV, Matayeva E, et al. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood. 2006;108:2655-2661.
45. Kretschmer K, Apostolou I, Hawiger D, et al. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. 2005;6:1219-1227.
46. Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4 (+) 25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862-2868.
47. Nurieva R, Yang XO, Martinez G, et al. Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448:480-483.
48. Li Y, Yee C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood. 2008;111:229-235.
49. Moroz A, Eppolito C, Li Q, et al. IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21. J Immunol. 2004;173:900-909.
50. Davis ID, Skrumsager BK, Cebon J, et al. An open-label, twoarm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma. Clin Cancer Res. 2007;13:3630-3636.